Current Oncology Reports最新文献_第10页

Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors 神经内分泌肿瘤患者的放射性核素治疗进展

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-10 DOI: 10.1007/s11912-024-01521-w

Denise S. Hoogenkamp, Linda J. de Wit–van der Veen, Daphne M. V. Huizing, Margot E. T. Tesselaar, Rachel S. van Leeuwaarde, Marcel P. M. Stokkel, Marnix G. E. H. Lam, Arthur J. A. T. Braat

{"title":"Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors","authors":"Denise S. Hoogenkamp, Linda J. de Wit–van der Veen, Daphne M. V. Huizing, Margot E. T. Tesselaar, Rachel S. van Leeuwaarde, Marcel P. M. Stokkel, Marnix G. E. H. Lam, Arthur J. A. T. Braat","doi":"10.1007/s11912-024-01521-w","DOIUrl":"https://doi.org/10.1007/s11912-024-01521-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, PRRT shows promising first results as a treatment prior to surgery.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>There is great demand to enhance the efficacy of PRRT through combination with other anticancer treatments. While research in this area is currently limited, the field is rapidly evolving with numerous ongoing clinical trials aiming to address this need and explore novel therapeutic combinations.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140592775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer 转移性钙化敏感性前列腺癌患者的现有系统疗法

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-09 DOI: 10.1007/s11912-024-01509-6

Guillaume Grisay, Pernelle Lavaud, Karim Fizazi

{"title":"Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer","authors":"Guillaume Grisay, Pernelle Lavaud, Karim Fizazi","doi":"10.1007/s11912-024-01509-6","DOIUrl":"https://doi.org/10.1007/s11912-024-01509-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>This review aims to explore the evolving landscape of treatments available for metastatic castration-sensitive prostate cancer (mCSPC) patients.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>In less than a decade, evidence was chronologically provided that (1) systemic treatment intensification with docetaxel improves outcomes, including survival, in men with mCSPC, (2) then that these outcomes are also improved when a second-generation androgen receptor pathway inhibitor (ARPI) is combined with androgen deprivation therapy (ADT), and (3) using a “triplet systemic therapy,” which consists in the combination of ADT, an ARPI and docetaxel, further improves outcomes, including survival. Radiotherapy to the prostate combined with ADT alone is now recommended in men with low-volume mCSPC. Combining prostate radiotherapy and intensified systemic treatment including abiraterone may be synergistic as suggested in the PEACE-1 trial. Also, the role of metastases-directed local therapies (mostly stereotactic radiotherapy) is currently being assessed in phase 3 trials. Finally, the integration of biomarkers (e.g. <i>BRCA2</i> gene alterations, <i>PTEN</i> loss, PSMA expression) for decision making is not currently established, though trials are also currently underway. Importantly, most evidence currently available was obtained in men with de novo metastases, while for those with metastatic relapse after definitive local treatment, the role of treatment intensification is less well established.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Treatment intensification is nowadays the standard of care for patients with de novo mCSPC as it leads to outcomes improvement, including survival, and the standard of care is evolving almost on a yearly basis.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140592923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune Checkpoint Inhibitors in Geriatric Oncology 老年肿瘤学中的免疫检查点抑制剂

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-08 DOI: 10.1007/s11912-024-01528-3

Sarah L. Cook, Md Al Amin, Shahla Bari, Pradeep J. Poonnen, Mustafa Khasraw, Margaret O. Johnson

{"title":"Immune Checkpoint Inhibitors in Geriatric Oncology","authors":"Sarah L. Cook, Md Al Amin, Shahla Bari, Pradeep J. Poonnen, Mustafa Khasraw, Margaret O. Johnson","doi":"10.1007/s11912-024-01528-3","DOIUrl":"https://doi.org/10.1007/s11912-024-01528-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>This manuscript will update prior reviews of immune checkpoint inhibitors (ICIs) in light of basic science, translational, and clinical discoveries in the field of cancer immunology and aging.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>ICIs have led to significant advancements in the treatment of cancer. Landmark trials of ICIs have cited the efficacy and toxicity experienced by older patients, but most trials are not specifically designed to address outcomes in older patients. Underlying mechanisms of aging, like cellular senescence, affect the immune system and may ultimately alter the host’s response to ICIs. Validated tools are currently used to identify older adults who may be at greater risk of developing complications from their cancer treatment.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>We review changes in the aging immune system that may alter responses to ICIs, report outcomes and toxicities in older adults from recent ICI clinical trials, and discuss clinical tools specific to older patients with cancer.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140593163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient Navigation in Cancer Treatment: A Systematic Review 癌症治疗中的患者导航：系统回顾

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-06 DOI: 10.1007/s11912-024-01514-9

Matthew Chen, Victoria S. Wu, Derek Falk, Chesley Cheatham, Jennifer Cullen, Richard Hoehn

{"title":"Patient Navigation in Cancer Treatment: A Systematic Review","authors":"Matthew Chen, Victoria S. Wu, Derek Falk, Chesley Cheatham, Jennifer Cullen, Richard Hoehn","doi":"10.1007/s11912-024-01514-9","DOIUrl":"https://doi.org/10.1007/s11912-024-01514-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Patient navigation promotes access to timely treatment of chronic diseases by eliminating barriers to care. Patient navigation programs have been well-established in improving screening rates and diagnostic resolution. This systematic review aimed to characterize the multifaceted role of patient navigators within the realm of cancer treatment.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>A comprehensive electronic literature review of PubMed and Embase databases was conducted to identify relevant studies investigating the role of patient navigators in cancer treatment from August 1, 2009 to March 27, 2023.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Fifty-nine articles were included in this review. Amongst studies focused on cancer treatment initiation, 70% found a significant improvement in treatment initiation amongst patients who were enrolled in patient navigation programs, 71% of studies focused on treatment adherence demonstrated significant improvements in treatment adherence, 87% of studies investigating patient satisfaction showed significant benefits, and 81% of studies reported a positive impact of patient navigators on quality care indicators. Three palliative care studies found beneficial effects of patient navigation. Thirty-seven studies investigated disadvantaged populations, with 76% of them concluded that patient navigators made a positive impact during treatment. This systematic review provides compelling evidence supporting the value of patient navigation programs in cancer treatment. The findings suggest that patient navigation plays a crucial role in improving access to care and optimizing treatment outcomes, especially for disadvantaged cancer patients. Incorporating patient navigation into standard oncology practice can reduce disparities and improve the overall quality of cancer care.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140592678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update 神经内分泌肿瘤的放射性核素放射治疗：最新进展

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-06 DOI: 10.1007/s11912-024-01526-5

Martina Di Franco, Lucia Zanoni, Emilia Fortunati, Stefano Fanti, Valentina Ambrosini

{"title":"Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update","authors":"Martina Di Franco, Lucia Zanoni, Emilia Fortunati, Stefano Fanti, Valentina Ambrosini","doi":"10.1007/s11912-024-01526-5","DOIUrl":"https://doi.org/10.1007/s11912-024-01526-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of combined diagnosis with positron emission tomography (PET) and treatment with peptide receptor radionuclide therapy (PRRT).</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Following NETTER-1 trial, PRRT with [177Lu]Lu-DOTATATE was approved by FDA and EMA and is routinely employed in advanced G1 and G2 SST (somatostatin receptor)-expressing NET. Different approaches have been proposed so far to improve the PRRT therapeutic index, encompassing re-treatment protocols, combinations with other therapies and novel indications. Molecular imaging holds a potential added value in characterizing disease biology and heterogeneity using different radiopharmaceuticals (e.g., SST and FDG) and may provide predictive and prognostic parameters. Response assessment criteria are still an unmet need and new theranostic pairs showed preliminary encouraging results.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>PRRT for NET has become a paradigm of modern theranostics. PRRT holds a favorable toxicity profile, and it is associated with a prolonged time to progression, reduction of symptoms, and improved patients’ quality of life. In light of further optimization, different new strategies have been investigated, along with the development of new radiopharmaceuticals.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140593093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative Neurocognitive Function in Glioma Surgery 胶质瘤手术围手术期的神经认知功能

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-04 DOI: 10.1007/s11912-024-01522-9

Kyle R. Noll, Mariana Bradshaw, David Sheppard, Jeffrey S. Wefel

{"title":"Perioperative Neurocognitive Function in Glioma Surgery","authors":"Kyle R. Noll, Mariana Bradshaw, David Sheppard, Jeffrey S. Wefel","doi":"10.1007/s11912-024-01522-9","DOIUrl":"https://doi.org/10.1007/s11912-024-01522-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>This review provides a concise overview of the recent literature regarding preoperative and postoperative neurocognitive functioning (NCF) in patients with glioma. Brief discussion also covers contemporary intraoperative brain mapping work, with a focus on potential influence of mapping upon NCF outcomes following awake surgery.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Most patients with glioma exhibit preoperative NCF impairment, with severity varying by germ line and tumoral genetics, tumor grade, and lesion location, among other characteristics. Literature regarding postoperative NCF changes is mixed, though numerous studies indicate a majority of patients exhibit immediate and short-term worsening. This is often followed by recovery over several months; however, a substantial portion of patients harbor persisting declines. Decline appears related to surgically-induced structural and functional brain alterations, both local and distal to the tumor and resection cavity. Importantly, NCF decline may be mitigated to some extent by intraoperative brain mapping, including mapping of both language-mediated and nonverbal functions.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Research regarding perioperative NCF in patients with glioma has flourished over recent years. While this has increased our understanding of contributors to NCF and risk of decline associated with surgical intervention, more work is needed to better preserve NCF throughout the disease course.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140592780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Trends and Challenges of Microbiome Research in Prostate Cancer 前列腺癌微生物组研究的当前趋势与挑战

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-04 DOI: 10.1007/s11912-024-01520-x

Shaun Trecarten, Bernard Fongang, Michael Liss

{"title":"Current Trends and Challenges of Microbiome Research in Prostate Cancer","authors":"Shaun Trecarten, Bernard Fongang, Michael Liss","doi":"10.1007/s11912-024-01520-x","DOIUrl":"https://doi.org/10.1007/s11912-024-01520-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>The role of the gut microbiome in prostate cancer is an emerging area of research interest. However, no single causative organism has yet been identified. The goal of this paper is to examine the role of the microbiome in prostate cancer and summarize the challenges relating to methodology in specimen collection, sequencing technology, and interpretation of results.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Significant heterogeneity still exists in methodology for stool sampling/storage, preservative options, DNA extraction, and sequencing database selection/in silico processing. Debate persists over primer choice in amplicon sequencing as well as optimal methods for data normalization. Statistical methods for longitudinal microbiome analysis continue to undergo refinement.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>While standardization of methodology may help yield more consistent results for organism identification in prostate cancer, this is a difficult task due to considerable procedural variation at each step in the process. Further reproducibility and methodology research is required.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140592779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas. 脑脊液液体活检在成人胶质瘤评估中的应用

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-01 Epub Date: 2024-03-15 DOI: 10.1007/s11912-024-01517-6

Allison R Valerius, Mason J Webb, Nouran Hammad, Ugur Sener, Rachna Malani

{"title":"Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas.","authors":"Allison R Valerius, Mason J Webb, Nouran Hammad, Ugur Sener, Rachna Malani","doi":"10.1007/s11912-024-01517-6","DOIUrl":"10.1007/s11912-024-01517-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to discuss recent research regarding the biomolecules explored in liquid biopsies and their potential clinical uses for adult-type diffuse gliomas.</p><p><strong>Recent findings: </strong>Evaluation of tumor biomolecules via cerebrospinal fluid (CSF) is an emerging technology in neuro-oncology. Studies to date have already identified various circulating tumor DNA, extracellular vesicle, micro-messenger RNA and protein biomarkers of interest. These biomarkers show potential to assist in multiple avenues of central nervous system (CNS) tumor evaluation, including tumor differentiation and diagnosis, treatment selection, response assessment, detection of tumor progression, and prognosis. In addition, CSF liquid biopsies have the potential to better characterize tumor heterogeneity compared to conventional tissue collection and CNS imaging. Current imaging modalities are not sufficient to establish a definitive glioma diagnosis and repeated tissue sampling via conventional biopsy is risky, therefore, there is a great need to improve non-invasive and minimally invasive sampling methods. CSF liquid biopsies represent a promising, minimally invasive adjunct to current approaches which can provide diagnostic and prognostic information as well as aid in response assessment.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140136599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients. 改善乳腺癌患者福祉的综合护理方法。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-01 Epub Date: 2024-02-24 DOI: 10.1007/s11912-024-01500-1

Alessandra Fabi, Alessandro Rossi, Edoardo Mocini, Ludovica Cardinali, Valerio Bonavolontà, Cristina Cenci, Stefano Magno, Vittoria Barberi, Antimo Moretti, Zein Mersini Besharat, Giovanni Iolascon, Carlo Baldari, Elisabetta Ferretti, Andrea Botticelli, Ida Paris, Giovanni Scambia, Silvia Migliaccio

{"title":"An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients.","authors":"Alessandra Fabi, Alessandro Rossi, Edoardo Mocini, Ludovica Cardinali, Valerio Bonavolontà, Cristina Cenci, Stefano Magno, Vittoria Barberi, Antimo Moretti, Zein Mersini Besharat, Giovanni Iolascon, Carlo Baldari, Elisabetta Ferretti, Andrea Botticelli, Ida Paris, Giovanni Scambia, Silvia Migliaccio","doi":"10.1007/s11912-024-01500-1","DOIUrl":"10.1007/s11912-024-01500-1","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) treatment has recently been revolutionized by the introduction of newer targeted agents, that helped tailoring therapies around the single patient. Along with increased survival rates, a careful evaluation of diet, lifestyle habits, physical activity, emotional and psychological experiences linked to the treatment journey, is now mandatory. However, a true proposal for an omnicomprehensive and \"integrative\" approach is still lacking in literature.</p><p><strong>Methods: </strong>A scientific board of internationally recognized specialists throughout different disciplines designed a shared proposal of holistic approach for BC patients.</p><p><strong>Results: </strong>A narrative review, containing information on BC treatment, endocrinological and diet aspects, physical activity, rehabilitation, integrative medicine, and digital narrative medicine, was developed.</p><p><strong>Conclusions: </strong>In the context of a patient-centered care, BC treatment cannot be separated from a patient's long-term follow-up and care, and an organized interdisciplinary collaboration is the future in this disease's cure, to make sure that our patients will live longer and better.</p><p><strong>Trial registration: </strong>NCT05893368: New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer (PERGIQUAL). Registration date: 29th May 2023.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11021235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139944018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Update on the Management of Bone Metastases. 骨转移瘤治疗的最新进展。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-04-01 Epub Date: 2024-03-28 DOI: 10.1007/s11912-024-01515-8

Alexander J Grosinger, Sara R Alcorn

{"title":"An Update on the Management of Bone Metastases.","authors":"Alexander J Grosinger, Sara R Alcorn","doi":"10.1007/s11912-024-01515-8","DOIUrl":"10.1007/s11912-024-01515-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>Increasing life expectancy among patients with advanced cancer has placed a greater emphasis on optimizing pain control and quality of life. Concurrently, significant advancements in radiotherapy for bone metastases have permitted for dose escalation strategies such as stereotactic radiotherapy. This review aims to provide updated information on the management of bone metastases in light of these developments.</p><p><strong>Recent findings: </strong>We reviewed recent studies regarding the role and details of external beam radiotherapy for bone metastases, with emphasis on differences by treatment site as well as intention (palliative versus ablative for oligometastases). Conventional palliative radiotherapy remains a mainstay of management. While stereotactic radiotherapy may augment durability of pain relief and even survival time, there are significant questions remaining regarding optimal dosing and patient selection. Radiotherapy for bone metastases continues to evolve, particularly with increasing use of stereotactic radiotherapy. Future studies are needed to clarify optimal dose, fractionation, modality, and patient selection criteria among different radiotherapy approaches.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11021281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0